New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?

Global burden of recurrent vulvovaginal candidiasis: a systematic review

Denning, D. W., Kneale, M., Sobel, J. D., & Rautemaa-Richardson, R. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30103-8 · Cited by 639 · see citing works

Recurrent vulvovaginal candidiasis

Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.06.067 · Cited by 502 · see citing works

Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis

Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487 · see citing works

Estimation of Direct Healthcare Costs of Fungal Diseases in the United States

Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438 · see citing works

Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States: Results From an Internet Panel Survey

Foxman, B., Muraglia, R., Dietz, J.-P., Sobel, J. D., & Wagner, J. (2013) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e318273e8cf · Cited by 261 · see citing works

Fluconazole-Resistant Candida albicans Vulvovaginitis

Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195 · see citing works

An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis

Makanjuola, O., Bongomin, F., & Fayemiwo, S. (2018) · Journal of Fungi · doi:10.3390/jof4040121 · Cited by 182 · see citing works

Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002

Pfaller, M. A., Messer, S. A., Boyken, L. B., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3142-3146.2004 · Cited by 181 · see citing works

Recurrent vulvovaginal candidiasis

Blostein, F., Levin-Sparenberg, E., Wagner, J., & Foxman, B. (2017) · Annals of Epidemiology · doi:10.1016/j.annepidem.2017.08.010 · Cited by 180 · see citing works

The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme

Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173 · see citing works

Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole

Sobel, J. D., Kapernick, P. S., Zervos, M., Reed, B. D., Hooton, T., Soper, D., Nyirjesy, P., Heine, M. W., Willems, J., Panzer, H., et al. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.115116 · Cited by 158 · see citing works

Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial)

Donders, G., Bellen, G., Byttebier, G., Verguts, L., Hinoul, P., Walckiers, R., Stalpaert, M., Vereecken, A., & Van Eldere, J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.06.029 · Cited by 127 · see citing works

Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA

Aballéa, S., Guelfucci, F., Wagner, J., Khemiri, A., Dietz, J.-P., Sobel, J. D., & Toumi, M. (2013) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-11-169 · Cited by 126 · see citing works

Treatment of vulvovaginal candidiasis: a review of the literature

Dovnik, A., Golle, A., Novák, D., Arko, D., & Takač, I. (2015) · Acta Dermatovenerologica Alpina Pannonica et Adriatica · doi:10.15570/actaapa.2015.2 · Cited by 107 · see citing works

<i>De Novo</i> Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance

Jiménez-Ortigosa, C., Perez, W. B., Angulo, D., Borroto-Esoda, K., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-17 · Cited by 89 · see citing works

SCY-078 is fungicidal against Candida species in time-kill studies

Scorneaux, B., Angulo, D., Borroto-Esoda, K., Ghannoum, M., Peel, M., & Wring, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01961-16 · Cited by 88 · see citing works

Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections

Martens, M. G., Maximos, B., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., Flynt, A., & Brand, S. R. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.023 · Cited by 86 · see citing works

Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors

Yates, C. M., Garvey, E. P., Shaver, S. R., Schotzinger, R. J., & Hoekstra, W. J. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.037 · Cited by 85 · see citing works

Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis

Garvey, E. P., HOEKSTRA, W., Schotzinger, R. J., Sobel, J. D., Lilly, E. A., & Fidel, P. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00185-15 · Cited by 83 · see citing works

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

Schwebke, J. R., Sobel, R., Gersten, J. K., Sussman, S. A., Lederman, S. N., Jacobs, M. A., Chappell, B. T., Weinstein, D. L., Moffett, A. H., Azie, N. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab750 · Cited by 82 · see citing works

Association of a variable number tandem repeat in the NLRP3 gene in women with susceptibility to RVVC

Jaeger, M., Carvalho, A., Cunha, C., Plantinga, T. S., van de Veerdonk, F. L., Puccetti, M., Galosi, C., Joosten, L. A. B., Dupont, B., Kullberg, B. J., et al. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2600-5 · Cited by 77 · see citing works

Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents

Wiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 68 · see citing works

Alopecia Associated with Fluconazole Therapy

Pappas, P. G., Kauffman, C. A., Perfect, J., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-5-199509010-00006 · Cited by 66 · see citing works

A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis

Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61 · see citing works

Genetic Basis for Recurrent Vulvo-Vaginal Candidiasis

Jaeger, M., Plantinga, T. S., Joosten, L. A. B., Kullberg, B. J., & Netea, M. G. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0319-3 · Cited by 60 · see citing works

Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans

Collins, L. M., Moore, R., & Sobel, J. D. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000496 · Cited by 55 · see citing works

Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis

Sobel, J. D., Donders, G., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., & Brand, S. R. (2022) · NEJM Evidence · doi:10.1056/evidoa2100055 · Cited by 55 · see citing works

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)

Sobel, R., Nyirjesy, P., Ghannoum, M. A., Delchev, D., Azie, N., Angulo, D., Harriott, I., Borroto–Esoda, K., & Sobel, J. D. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16972 · Cited by 54 · see citing works

A Novel 1,3-Beta- d -Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis

Larkin, E. L., Long, L., Isham, N. C., Borroto–Esoda, K., Barat, S., Angulo, D., Wring, S., & Ghannoum, M. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02611-18 · Cited by 52 · see citing works

Oral Ibrexafungerp: An Investigational Agent for the Treatment of Vulvovaginal Candidiasis

Azie, N., Angulo, D., Dehn, B., & Sobel, J. D. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791820 · Cited by 46 · see citing works

The Discovery and Profile of Fluconazole

Richardson, K. (1990) · Journal of Chemotherapy · doi:10.1080/1120009x.1990.11738981 · Cited by 32 · see citing works

Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

Nishimoto, A. T., Whaley, S., Wiederhold, N. P., Zhang, Q., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01304-19 · Cited by 31 · see citing works

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis

Sobel, J. D., Borroto–Esoda, K., Azie, N. E., & Angulo, D. A. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00562-21 · Cited by 26 · see citing works

Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods

Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84 · see citing works

How do I manage refractory invasive pulmonary aspergillosis

Vergidis, P., Sendi, P., Alkhateeb, H. B., & Nguyen, M. H. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.01.015 · Cited by 12 · see citing works

Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies

e Silva, D. M., de Souza Lacerda, L., de Souza Andrioli, A., Braz, W. R., Campos, L. M., de Paiva, M. R. B., Pittella, F., Fabri, R. L., & Tavares, G. D. (2025) · Fundamental &amp; Clinical Pharmacology · doi:10.1111/fcp.70046 · Cited by 7 · see citing works

Comparison between Fluconazole with Oral Protexin Combination and Fluconazole in the Treatment of Vulvovaginal Candidiasis

Nouraei, S., Akbari, S. A. A., Jorjani, M., Majd, H. A., Afrakhteh, M., Ghafoorian, A., & Harandi, H. T. (2012) · ISRN Obstetrics and Gynecology · doi:10.5402/2012/375806 · Cited by 19 · see citing works

Clinic Effect of Fluconazole in Patients with Vulvovaginal Candidiasis(Analysis of 50 Cases)

Zhi-li, F. (2009) · Zhongguo chuji weisheng baojian

Clinical Study of Fluconazole Mycostatin Combined Canesten to Treat Recurrent Vulvovaginal Candidiasis

Zhao, B. (2010) · Journal of Medical Forum

Efficacy of fluconazole in treatment of vulvovaginal candidiasis infection of college student patients

Guang-hu, Y. (2011) · Zhongguo xiao-yi

Persistent vulvovaginal candidiasis: systemic treatment with oral fluconazole.

Frega, A., Gallo, G., Renzi, F. D., et al. (1994) · PubMed · Cited by 2 · see citing works